An interventional study of Hybrid Closed-Loop Artificial Pancreas System in T2DM Patients With Traumatic Brain Injury, sponsored by Shanxi Bethune Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-04-23.
Sponsored by Shanxi Bethune Hospital · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Brain Injuries, Traumatic with a site in China — 29 open to participants now, 30 under way, none of them phase 3. Brain Injuries, Traumatic · China.
Among the 60 studies in Brain Injuries, Traumatic with a site in China, this one is the 21st largest by planned enrollment of the 26 interventional ones that give a count, is one of 7 that started in 2025, is one of 18 with no phase, reaches primary completion later than 20 of the 29 other live ones, and was the 51st registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →29 of the 60 studies in Brain Injuries, Traumatic with a site in China are open now. Recruiting first, the newest first:
Zhangjiagang First People's Hospital · Sites in China
Ages 18–65
Shanghai 6th People's Hospital · Sites in China
Ages 18–80 · Healthy volunteers
Huaqiu Zhang · Sites in China
Ages 18–60
Tang-Du Hospital · Sites in China
Ages 18–75
Second Affiliated Hospital, Zhejiang University, School of Medicine · Sites in China
Ages 18–90
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 3 · Phase 3 1 · Phase 4 3
First in 2006; this study’s year is marked. 7 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 83 across the 26 interventional studies, 110 across the 34 observational. Of the 11 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 60 has an industry lead sponsor. The 10 most frequent:
Shanxi Bethune Hospital is the lead sponsor of 23 studies on the registry; 22 are open to participants now.
Shanxi Bethune Hospital has 1 study filed under Brain Injuries, Traumatic — fewer than ten, so there is no comparison to draw.
7 of the studies in Brain Injuries, Traumatic with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07115459Xiangya Hospital of Central South UniversityDevelopment and Validation of a Prognostic Model for Neurocritical Patients Using Multimodal Brain Monitoring | 2026-12-31 |
| NCT06429774Beijing Tiantan HospitalComparative Effectiveness of Intervention in Multi-level Hospitals for Acute Traumatic Brain Injury(Metric-TBI) | 2026-12-31 |
| NCT04900168Tang-Du HospitalIntracranial Pressure Monitoring in Moderate Traumatic Brain Injury | 2026-12-31 |
| NCT06241482Shanghai 6th People's HospitalSafety and Efficacy of Enhanced Recovery After Surgery in Neurocritical Care | 2027-04-30 |
| NCT06909071Shanxi Bethune HospitalHybrid Closed-Loop System in Neurosurgical Perioperative Hyperglycemia: An Open RCT | 2027-06-30 |
Add all 7 to your calendar (.ics) → With an account.
Among the 60 studies in Brain Injuries, Traumatic with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this study, we plan to use an open-source hybrid closed-loop artificial pancreas system and a combination of a traditional insulin pump and continuous glucose monitoring (CGM) respectively to conduct short-term intensive insulin treatment for patients with type 2 diabetes mellitus (T2DM) during the perioperative period who are hospitalized in the Department of Neurosurgery of Shanxi Bethune Hospital. By comparing the blood glucose control status of patients under different intensive insulin treatment regimens and other clinical indicators such as postoperative complications, we will comprehensively evaluate the clinical efficacy and safety of the hybrid closed-loop artificial pancreas system.
According to the inclusion and exclusion criteria, 40 perioperative patients with type 2 diabetes mellitus (T2DM) will be screened and enrolled from the neurosurgical ward of Shanxi Bethune Hospital. They will be randomly divided into two groups: 20 patients in the hybrid closed-loop artificial pancreas system group and 20 patients in the traditional pump combined with continuous glucose monitoring (CGM) group. Both groups of patients will use continuous glucose monitoring to measure blood glucose levels. After collecting baseline data, the two groups of patients will receive short-term intensive insulin therapy according to the above-mentioned plans. Relevant clinical data will be collected during and after the treatment to compare the advantages and disadvantages of the two intensive insulin treatment plans in controlling blood glucose levels in perioperative T2DM patients undergoing neurosurgery and their impact on complications.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on the patient's weight, the total daily insulin requirement is calculated at 0.3\~0.6U/(kg\*d) and distributed before meals according to the specific conditions of the patient. Continuous glucose monitoring system is used along with daily capillary blood glucose monitoring (fasting, 2 hours after breakfast, lunch, and dinner, totaling 4 times). Insulin doses are adjusted according to the patient's blood glucose level until the target blood glucose level is achieved.
Device: Hybrid Closed-Loop Artificial Pancreas System
The open-source hybrid closed-loop artificial pancreas system, utilizing ultra-rapid-acting insulin, was employed for perioperative blood glucose management in neurosurgery. Insulin requirements were calculated based on patient weight. The system auto-adjusted basal rates according to blood glucose, while bolus treatments were manually inputted by nurses following physician instructions. Continuous and daily capillary blood glucose monitoring were conducted.
Device: Hybrid Closed-Loop Artificial Pancreas System
The total daily insulin requirement is calculated as 0.3 - 0.6 U/(kg·d) according to patient's weight. The system automatically adjusts the basal rate during operation. Nurses enter bolus dose orders in AAPS software as directed by physicians. Blood glucose is monitored via continuous glucose monitoring and 4 daily fingerstick measurements (fasting and 2 hours after each meal).
Time in Range (TIR)
The percentage of time that blood glucose is within the target range of 6.0-12.0 mmol/L. The calculation formula is: TIR = (Time within the target range / Total time) × 100%
Time frame: During the 5- to 7-day period of hospitalization
Blood glucose target criteria
FPG (fasting plasma glucose) or pre-prandial blood glucose of 8\~10 mmol/L, 2hPG (2-hour postprandial glucose) or blood glucose at any time point when unable to eat is 8\~12 mmol/L. General criteria: FPG or pre-prandial blood glucose of 6\~8 mmol/L, 2hPG or blood glucose at any time point when unable to eat is 8\~10 mmol/L (Expert Consensus on Perioperative Blood Glucose Monitoring for Adults - 2021) . The blood glucose target achievement rate within 1 week of insulin intensification therapy is calculated using the formula: Blood glucose target achievement rate = Number of patients achieving blood glucose targets / Total number of patients \* 100%.
Time frame: During the 5- to 7-day period of hospitalization
Time Below Range (TBR)、Time Above Range (TAR)
Time Below Range (TBR) refers to the percentage of time when blood glucose is below the target range, that is, blood glucose \< 3.9 mmol/L. The calculation formula is: TBR = (Time with blood glucose \< 3.9 mmol/L) / Total Time × 100%. Time Above Range (TAR) refers to the percentage of time when blood glucose is above the target range, that is, blood glucose \> 10.0 mmol/L. The calculation formula is: TAR = (Time with blood glucose \> 10.0 mmol/L) / Total Time × 100%.
Time frame: During the 5- to 7-day period of hospitalization
Hypoglycemia Incidence Rate
Using a blood glucose range of 3.0 - 3.9 mmol/L as the diagnostic criterion for hypoglycemia, the incidence of hypoglycemia during the treatment process in the two groups was counted and compared. Taking a blood glucose level \< 3.0 mmol/L as the diagnostic criterion for severe hypoglycemia, the incidence of severe hypoglycemia during the treatment process in the two groups was also counted and compared.
Time frame: During the 5- to 7-day period of hospitalization
Blood glucose fluctuation level (IQR)
The 25th and 75th percentile values of the blood glucose fluctuation range
Time frame: During the 5- to 7-day period of hospitalization
Perioperative Infection Rate and Inflammatory Markers
The percentage of patients with fever, positive bacterial culture of incision secretions, other secretions or blood during the perioperative period, calculated as (Number of patients with positive results / Total number of patients) × 100%. Perioperative inflammatory indicators include white blood cell count (WBC), percentage of neutrophils, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin, etc.
Time frame: During the 5- to 7-day period of hospitalization
Adverse event(AE)、Serious adverse event(SAE)
Adverse events are defined as any unfavorable medical events that occur during the use of the investigational medical device, regardless of whether they are related to the device. Serious adverse events are defined as events that result in death or a serious deterioration of the health status during the clinical trial. The incidences of adverse events and serious adverse events during the treatment process in the three groups were statistically analyzed and compared.
Time frame: During the 5- to 7-day period of hospitalization
Perioperative infection rate and inflammatory markers
The perioperative infection rate is calculated as the number of patients who develop fever, have incision secretions, positive bacterial cultures from other secretions or blood during the perioperative period divided by the total number of patients, multiplied by 100%. Perioperative inflammatory markers include white blood cell count (WBC), percentage of neutrophils, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), procalcitonin, etc.
Time frame: During the 5- to 7-day period of hospitalization
Suture removal time, total hospital stay days, and postoperative hospital stay days
Suture removal time, total hospital stay days, and postoperative hospital stay days
Time frame: During the 5- to 7-day period of hospitalization
Plan to share: No — If there is a need to use data, please contact the person in charge and follow the relevant procedures to achieve data sharing. Without permission, do not use the data directly.
No publications or documents are linked to this record.
Start is estimated for Apr 2025; primary completion for Jun 2027, 26 months later.
Of 445 non-industry interventional studies with no phase under Brain Injuries, Traumatic, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 64. This study's planned 26 months is below that.
Counting every sponsor, half of 467 studies reached it within 41 months; a quarter within 22 and three quarters within 64.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Shanxi Bethune Hospital